CHAPEL HILL, N.C., June 16, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, will host an Analyst and Investor Day on Thursday, June 23, 2016, from 8:30 a.m. to 11:30 a.m. EDT in New York City. Prabhavathi Fernandes, Ph.D., president and chief executive officer, and other members of the Cempra management team will provide a comprehensive update of commercialization plans for solithromycin in patients with community-acquired bacterial pneumonia (CABP), a review of the CABP market and need for new CABP drugs. In addition, notable physician experts will discuss their perspective on this disease and Cempa’s pipeline of drug candidates.
Interested parties may access a live audio webcast and slides of the presentations on the investor section of Cempra’s website at www.cempra.com beginning at 8:30 a.m. EDT. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.
Investors viewing the live webcast, who would like to ask management a question, can do so by emailing their question to robert.uhl@westwicke.com either in advance or in real time.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and new drug applications for the intravenous and oral capsule formulations have been submitted to the FDA. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.